DK1173201T3 - Fremgangsmåde til behandling af fibrose ved anvendelse af en antagonist af integrin-alfa-4-underenheden - Google Patents

Fremgangsmåde til behandling af fibrose ved anvendelse af en antagonist af integrin-alfa-4-underenheden

Info

Publication number
DK1173201T3
DK1173201T3 DK00926238T DK00926238T DK1173201T3 DK 1173201 T3 DK1173201 T3 DK 1173201T3 DK 00926238 T DK00926238 T DK 00926238T DK 00926238 T DK00926238 T DK 00926238T DK 1173201 T3 DK1173201 T3 DK 1173201T3
Authority
DK
Denmark
Prior art keywords
subunit
antagonist
treating fibrosis
integrin alpha
integrin
Prior art date
Application number
DK00926238T
Other languages
English (en)
Inventor
Philip Gotwals
Roy R Lobb
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1173201T3 publication Critical patent/DK1173201T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00926238T 1999-04-22 2000-04-21 Fremgangsmåde til behandling af fibrose ved anvendelse af en antagonist af integrin-alfa-4-underenheden DK1173201T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13084799P 1999-04-22 1999-04-22
US13721499P 1999-06-01 1999-06-01
PCT/US2000/010781 WO2000064474A1 (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Publications (1)

Publication Number Publication Date
DK1173201T3 true DK1173201T3 (da) 2005-09-12

Family

ID=26828876

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00926238T DK1173201T3 (da) 1999-04-22 2000-04-21 Fremgangsmåde til behandling af fibrose ved anvendelse af en antagonist af integrin-alfa-4-underenheden

Country Status (31)

Country Link
US (3) US6652856B2 (da)
EP (1) EP1173201B1 (da)
JP (3) JP5483515B2 (da)
KR (3) KR100746522B1 (da)
CN (3) CN100360183C (da)
AT (1) ATE298249T1 (da)
AU (1) AU783054B2 (da)
BG (2) BG65578B1 (da)
BR (1) BR0010669A (da)
CA (1) CA2370814C (da)
CY (1) CY1106046T1 (da)
CZ (1) CZ301636B6 (da)
DE (1) DE60020955T2 (da)
DK (1) DK1173201T3 (da)
EA (1) EA006681B1 (da)
EE (1) EE05662B1 (da)
ES (1) ES2243259T3 (da)
GE (1) GEP20063844B (da)
HK (2) HK1041452B (da)
HU (1) HU226383B1 (da)
IL (5) IL145898A0 (da)
IS (1) IS2259B (da)
MX (1) MXPA01010612A (da)
NO (1) NO330221B1 (da)
NZ (2) NZ515053A (da)
PL (1) PL198975B1 (da)
PT (1) PT1173201E (da)
RS (2) RS50086B (da)
SK (1) SK287328B6 (da)
TR (1) TR200200027T2 (da)
WO (1) WO2000064474A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50086B (sr) * 1999-04-22 2009-01-22 Biogen Idec Ma Inc., Upotreba antagonista subjedinica alfa-4 integrina za pripremanje farmaceutskog preparata za tretiranje fibroze
TR200103432T2 (tr) * 1999-06-01 2002-10-21 Biogen, Inc. Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
JP2003501395A (ja) * 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
ES2290120T3 (es) * 2000-03-17 2008-02-16 Avocet Polymer Technologies, Inc. Procedimientos para mejorar la dimension y el aspecto de una herida.
EP1341497A4 (en) * 2000-11-02 2005-10-19 Smithkline Beecham Corp RECEPTOR-LIPID ANTAGONIST CONJUGATES AND DELIVERY VEHICLES CONTAINING THE SAME
EA006705B1 (ru) * 2001-04-13 2006-02-24 Байоджен Айдек Ма Инк. Антитела против vla-1
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
EP1643969A2 (en) * 2003-07-11 2006-04-12 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005037313A2 (en) * 2003-10-17 2005-04-28 University Court Of The University Of Edinburgh Tissue repair by modulation of beta-1 integrin biological function
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
DK2034830T3 (da) * 2006-05-25 2014-10-27 Biogen Idec Inc Anti-vla-1-antistof til behandling af slagtilfælde
JP5659014B2 (ja) 2007-08-02 2015-01-28 ジリード バイオロジクス，インク． 線維症、腫瘍浸潤、血管新生及び転移の治療及び診断のための方法及び組成物
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
CN104487092B (zh) * 2012-03-28 2018-07-27 国立大学法人广岛大学 对于由阻碍整合素α8β1功能引起的纤维化的抑制
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
ATE150319T1 (de) * 1992-01-13 1997-04-15 Biogen Inc Behandlung von asthma
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
NZ262615A (en) * 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DK1759709T3 (da) * 1994-01-25 2013-06-10 Elan Pharm Inc Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4
PT759302E (pt) * 1994-04-26 2001-01-31 Akzo Nobel Nv Farmaco para o tratamento da artrite reumatoide
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
JPH10330268A (ja) * 1997-05-26 1998-12-15 Kureha Chem Ind Co Ltd ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤
PT1504764E (pt) * 1997-08-08 2009-01-14 Univ California Tratamento da fibrose hepática com anticorpos contra integrina alfa-v-beta 6
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
RS50086B (sr) * 1999-04-22 2009-01-22 Biogen Idec Ma Inc., Upotreba antagonista subjedinica alfa-4 integrina za pripremanje farmaceutskog preparata za tretiranje fibroze
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑

Also Published As

Publication number Publication date
CN1679935A (zh) 2005-10-12
IL206829A (en) 2013-06-27
IL182908A0 (en) 2007-08-19
CA2370814C (en) 2010-07-06
JP2002542300A (ja) 2002-12-10
KR20020000221A (ko) 2002-01-05
US20050281818A1 (en) 2005-12-22
NZ515053A (en) 2004-02-27
CN100360183C (zh) 2008-01-09
EA006681B1 (ru) 2006-02-24
IL206830A (en) 2013-06-27
KR20070050979A (ko) 2007-05-16
KR100837715B1 (ko) 2008-06-13
HK1041452B (zh) 2005-10-14
JP5483515B2 (ja) 2014-05-07
RS20080471A (en) 2010-12-31
BG65578B1 (bg) 2009-01-30
BG110115A (en) 2008-12-30
WO2000064474A8 (en) 2001-04-05
JP2014065747A (ja) 2014-04-17
US20020182213A1 (en) 2002-12-05
NO330221B1 (no) 2011-03-07
CN1356911A (zh) 2002-07-03
DE60020955T2 (de) 2006-05-11
ATE298249T1 (de) 2005-07-15
BR0010669A (pt) 2002-02-19
DE60020955D1 (de) 2005-07-28
IL182908A (en) 2010-11-30
SK287328B6 (sk) 2010-07-07
PT1173201E (pt) 2005-08-31
CA2370814A1 (en) 2000-11-02
HK1041452A1 (en) 2002-07-12
CZ20013754A3 (cs) 2002-07-17
CN1332714C (zh) 2007-08-22
EP1173201A1 (en) 2002-01-23
RS50086B (sr) 2009-01-22
SK15202001A3 (sk) 2002-09-10
AU4480000A (en) 2000-11-10
JP2007182453A (ja) 2007-07-19
IS6105A (is) 2001-10-11
PL198975B1 (pl) 2008-08-29
CN1191860C (zh) 2005-03-09
EP1173201B1 (en) 2005-06-22
AU783054B2 (en) 2005-09-22
HUP0201015A3 (en) 2004-12-28
GEP20063844B (en) 2006-06-12
CZ301636B6 (cs) 2010-05-12
WO2000064474A1 (en) 2000-11-02
CY1106046T1 (el) 2011-04-06
TR200200027T2 (tr) 2002-07-22
HK1076379A1 (en) 2006-01-20
EA200101116A1 (ru) 2002-04-25
HUP0201015A2 (hu) 2002-07-29
CN1596979A (zh) 2005-03-23
ES2243259T3 (es) 2005-12-01
EE05662B1 (et) 2013-06-17
NZ541431A (en) 2008-01-31
KR20070102760A (ko) 2007-10-19
HU226383B1 (hu) 2008-10-28
US6652856B2 (en) 2003-11-25
BG106118A (en) 2002-05-31
IL206829A0 (en) 2010-12-30
US20040037827A1 (en) 2004-02-26
IL145898A0 (en) 2002-07-25
NO20015122L (no) 2001-12-21
KR100746522B1 (ko) 2007-08-07
IS2259B (is) 2007-06-15
NO20015122D0 (no) 2001-10-19
PL351916A1 (en) 2003-06-30
IL206830A0 (en) 2010-12-30
MXPA01010612A (es) 2003-09-04
YU74901A (sh) 2004-07-15
IL145898A (en) 2007-07-24
BG66149B1 (bg) 2011-08-31
EE200100549A (et) 2002-12-16

Similar Documents

Publication Publication Date Title
DK1173201T3 (da) Fremgangsmåde til behandling af fibrose ved anvendelse af en antagonist af integrin-alfa-4-underenheden
DE69942037D1 (de) Humane monoklonale antikörper gegen ctla-4
ATE327004T1 (de) Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
DK1578936T3 (da) Humane anti-IFN-gamma-neutraliserende antistoffer som selektive inhibitorer af IFN-gamma-vejen
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
ATE254925T1 (de) Stimulierung des knochenwachstums mit peptidderivaten von thrombin
DK1003494T3 (da) (d)-metadon, et ikke-opioidt analgetikum
HUP0200152A3 (en) Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
PT1214302E (pt) 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas substituidas e sua utilizacao como inibidores de lipase
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
EA200001050A1 (ru) Малеат пароксетина
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
EP1666063A3 (en) Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
NO20003606L (no) Triazepinoner, fremgangsmÕte for deres fremstilling, samt deres terapeutiske anvendelse
EA200101271A1 (ru) Блокирующее моноклональное антитело к vla-1 и его применение для лечения воспалительных заболеваний